Key Points Big pharma still needs additional late-stage obesity drug assets. Viking’s obesity pipeline could attract major pharmaceutical acquisition interest. The company controls one of biotech’s most advanced independent obesity programs. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) increasingly looks like an acquisition candidate in biotech. But why? It's because large pharmaceutical companies are desperate to secure obesity drug exposure, and Viking controls one of the more advanced independent GLP-1/GIP programs still available. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Its lead obesity candidate, VK2735, is currently being developed in both injectable and oral formulations. The company's Phase 3 VANQUISH obesity studies are already fully enrolled, while management expects to initiate Phase 3 trials for the oral tablet later this year. The data for Viking's drug pipeline is strong In Viking's recent Phase 2 oral obesity study, patients achieved an average weight loss of up to 12.2% after 13 weeks, with no plateau observed during the trial. Earlier Phase 2 data involving the injectable version demonstrated up to 14.7% weight loss after 13 weeks. These results matter because the obesity market is becoming one of the largest pharmaceutical opportunities in decades. Analysts widely expect GLP-1 and dual agonist obesity therapies to eventually generate well over $100 billion annually. Eli Lilly and Novo Nordisk are already generating tens of billions in revenue from obesity and diabetes drugs like Zepbound and Wegovy. Here's the rub For large pharma companies, there aren't many late-stage obesity assets left to buy. That is where Viking becomes interesting. Unlike many smaller obesity drug developers, Viking still controls both injectable and oral v...

Key Points Prosight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter. The value of the firm’s Nektar Therapeutics position rose by $29.43 million in the quarter, reflecting both the share addition and stock price movement. This transaction represented a 1.68% change in the fund’s 13F reportable assets under management. After the trade, Prosight Management held 735,000 shares in Nektar Therapeutics, valued at $52.88 million as of March 31, 2026. 10 stocks we like better than Nektar Therapeutics › On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of Nektar Therapeutics (NASDAQ:NKTR), an estimated $10.27 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Prosight Management increased its position in Nektar Therapeutics by 180,367 shares. The estimated value of the additional shares is $10.27 million, calculated using the average closing price for the quarter ending March 31, 2026. The quarter-end value of the firm’s Nektar Therapeutics stake rose by $29.43 million, a figure that includes both trading activity and share price appreciation. What else to know Prosight Management was a net buyer in Nektar Therapeutics this quarter. The post-trade stake accounted for 8.67% of its 13F reportable AUM. Top five fund holdings after the filing: NASDAQ: NKTR: $52.88 million (8.7% of AUM) NYSE: BSX: $49.92 million (8.2% of AUM) NASDAQ: JANX: $49.34 million (8.1% of AUM) NASDAQ: PRCT: $48.64 million (8.0% of AUM) NASDAQ: LKFT: $46.50 million (7.6% of AUM) As of May 14, 2026, shares of Nektar Therapeutics were priced at $66.61, up nearly 600% over the past year and significantly outperforming the S&P 500, which is instead up about 28%. Company overview Metric Value Price (as of Friday) $66.61 Market capitalization $2.25 billion Revenue (TTM) $55.63 million Ne...

格隆汇5月24日｜据伊朗学生通讯社：埃及外长与美国驻西亚特使通电话，就美伊谈判最新进展进行磋商。

On May 15, 2026, Shapiro Capital Management disclosed a new position in Lionsgate Studios (NYSE:LION) , acquiring 9,309,570 shares in an estimated $85.91 million trade based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Shapiro Capital Management initiated a new position in Lionsgate Studios (NYSE:LION) by acquiring 9,309,570 shares. The estimated transaction value is $85.91 million, based on the average closing price for the first quarter of 2026. The quarter-end value of the position stood at $89.28 million, which reflects both the purchase and price changes during the period. Lionsgate Studios is a leading independent content producer and distributor, leveraging a vast portfolio of film and television assets to drive revenue and brand value. The company’s entrepreneurial approach and ownership of high-value franchises underpin its competitive position in the global entertainment industry. Strategic focus on content creation and multi-platform distribution enables Lionsgate to capitalize on evolving media consumption trends. Continue reading

UTHR260618P00380000 互動股市圖表 | UTHR Jun 2026 380.000 put 股市 Yahoo 財經

MP Materials (MP +4.41%) is a rare-earth mining company at the forefront of a massive effort to rebuild the U.S.'s domestic supply chain of rare-earth elements. And by "forefront," I mean it is pretty much standing alone. To date, no other U.S. company has what is under MP Materials' control. And no, I'm not talking about its partnership with Apple or its lucrative agreement with the Department of Defense (DOD) -- both, no doubt, key drivers behind MP stock's monster 223% gain last year. I'm referring to its key asset: the Mountain Pass mine, the only major rare-earth mine in operation in the U.S. today. Expand NYSE : MP MP Materials Today's Change ( 4.41 %) $ 2.72 Current Price $ 64.46 Key Data Points Market Cap $11B Day's Range $ 62.92 - $ 65.60 52wk Range $ 18.64 - $ 100.25 Volume 6.8M Avg Vol 6.1M Gross Margin 8.12 % Without MP's major mining facility in California and its Texas magnet factory to go with it, the U.S.'s ambition to break free from China's rare earths would have very little homegrown metal behind it, at least not enough above ground to refine into those highly sought-after high-performance magnets that every industry, from defense to tech, needs. And yet something isn't lining up. MP has inked major partnerships with the DOD and Apple; it has reported a strong first-quarter revenue beat; it's even transitioning into profitability -- yet the stock is flat in 2026, even dipping significantly at times back down toward pre-DOD levels. What gives? How could good news make the metal stock look worse? What's happening to America's rare-earth miner in 2026? The problem has always been MP's valuation. Indeed, despite its strategic importance to the U.S. rare-earth supply chain, the company's stock has run far, far ahead of its underlying business. Even at today's depressed price, it still trades about 37 times sales and more than 450 times forward earnings -- both of which scream anything but cheap. On top of that, the larger geopolitical context around MP...

特朗普在社交媒体发文称，与沙特、阿联酋、卡塔尔、巴基斯坦、土耳其、埃及、约旦、巴林等多国领导人，就伊朗及与和平相关的谅解备忘录事宜进行了非常顺利的通话。 目前协议已基本谈妥，待美国、伊朗及上述各国完成最终敲定。 此外，他还与以色列总理内塔尼亚胡进行了通话，同样进展顺利。协议的最终条款与细节目前正在讨论中，很快将对外公布。除协议的其他多项内容外，霍尔木兹海峡将恢复通航。 责任编辑：李桐

Six Nations. Champions Cup. Challenge Cup. Bordeaux Begles' demolition job over Leinster completed the European clean sweep for French men's rugby teams. Leinster, a side full to the brim of Irish internationals, did not have an answer as Bordeaux romped to a 41-19 victory in Bilbao to become only the sixth side to retain their European crown. That came less than 24 hours after Montpellier put in a similar showing against Ulster in the Challenge Cup final as they won the competition for the third time. Earlier in the year, after a dramatic conclusion to a thrilling tournament, France also retained their Six Nations title at the expense of Ireland. For Bordeaux, according to their Irish attack coach Noel McNamara, their inspiration came from Rory McIlroy, who won the Masters for the second time in April as he backed up his historic wait for the Green Jacket. The irony of a player from Northern Ireland being used as motivation will not be lost. "We spoke about Rory McIlroy in the lead-up to the quarter-final against Toulouse," McNamara told the BBC's Rugby Union Weekly podcast. "There's a beautiful ad that said good players want one Green Jacket and really good players want two, and we've got fantastic players. "That's what makes the game of rugby wonderful. They made a decision that one isn't enough. The challenge for us now is we're a young club, we're a new club and it's continuing to set that standard."

格隆汇5月24日｜特朗普在社交媒体上表示，他在白宫椭圆形办公室与沙特、阿联酋、卡塔尔、巴基斯坦、土耳其、埃及、约旦、巴林等多国领导人就伊朗问题及和平谅解备忘录进行了“非常好的通话”。特朗普称，协议已基本谈判完成，有待美国、伊朗及其他相关国家最终敲定。此外，他与以色列总理内塔尼亚胡的通话也“同样非常顺利”。协议的最终细节正在讨论中，将很快宣布。特朗普特别指出，除协议多项内容外，霍尔木兹海峡将被开放。

The stock market rebounded for solid weekly gains on Iran deal hopes, with talks continuing over the weekend. Tesla is near a buy point along with ASML and several other AI stocks.

Key Points Prosight bought 468,463 shares of GeneDx Holdings, estimated at $42.72 million based on average first-quarter 2026 prices. The quarter-end value of the position rose by $26.46 million, reflecting both trading and price moves. The transaction represented a 7% change relative to 13F AUM. Post-trade, Prosight held 523,463 WGS shares worth $33.62 million. 10 stocks we like better than GeneDx › On May 15, 2026, Prosight Management disclosed a purchase of 468,463 shares of GeneDx Holdings (NASDAQ:WGS), an estimated $42.72 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Prosight Management increased its holdings in GeneDx Holdings by 468,463 shares. The estimated transaction value, based on the average unadjusted closing price for the first quarter of 2026, was $42.72 million. The quarter-end value of the position, reflecting both price change and share addition, increased by $26.46 million to $33.62 million. What else to know The position now comprises roughly 5.51% of Prosight's 13F reportable assets under management. Top five holdings after the filing: NASDAQ: NKTR: $52.88 million (8.7% of AUM) NASDAQ: JANX: $49.34 million (8.1% of AUM) NASDAQ: PRCT: $48.64 million (8.0% of AUM) NYSE: BSX: $49.92 million (8.2% of AUM)) NASDAQ: LKFT: $46.50 million (7.6% of AUM) As of Friday, GeneDx shares were priced at $47.31, down 30% over the past year and well underperforming the S&P 500, which is instead up about 28% in the same period. Company overview Metric Value Price (as of Friday) $47.31 Market Capitalization $1.4 billion Revenue (TTM) $442.68 million Net Income (TTM) ($77.81 million) Company snapshot GeneDx Holdings Corp. provides health intelligence solutions, leveraging AI and machine learning to analyze clinical and genomic data through its Centrellis platform. The company operates in the healthcare information services sector, focusing on integrating AI-driven an...

宏福苑｜宏建、宏昌閣第二輪上樓 居民：盡量能帶走就帶走 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】宏福苑繼續第二輪上樓，宏建閣和宏昌閣將一連三日開放予居民回家執拾。 居民陸續到社區會堂登記，行李箱及大帆布袋幾乎都是居民必備，有居民穿起印有標語的衣服上樓。宏建閣和宏昌閣一連三天分批讓居民上樓，能再一次返回單位，居民都把握機會執拾或尋找要帶走的物品。 宏建閣居民黃先生：「最初都不知道會安排上樓多少次，其實第一次上樓已經執拾了重要東西。第二次是盡量，因為都不知道能否可以再回去。當然我們很希望回去，都不知道能否再回去時候當然能帶走就帶走。」

美国总统特朗普：协议已接近完成。 在该协议的其他核心要素之上，霍尔木兹海峡将会被重新开放。 目前正在就协议进行具体讨论，并将于近期正式宣布。 协议的最终细节与各方面条款目前正处于密集的讨论之中。 风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何意见、观点或结论是否符合其特定状况。据此投资，责任自负。

格隆汇5月24日｜美国总统特朗普：与多个穆斯林国家领导人就伊朗进行了交谈。

Key Points SpaceX plans to go public soon, and Goldman Sachs is serving as the lead underwriter. This IPO, along with other mega-deals, shows that dealmaking is on the upswing for Wall Street. Goldman Sachs reported strong first-quarter results and expects investment banking activity to accelerate as the year goes on. 10 stocks we like better than Goldman Sachs Group › It is shaping up to be a massive year for initial public offerings (IPO). SpaceX recently confirmed that it plans to go public next month in what is expected to be the largest IPO ever, with Goldman Sachs (NYSE: GS) serving as the lead underwriter. Over the past year, capital markets activity, which includes IPOs and mergers and acquisitions (M&A), has picked up amid strong public markets and a favorable regulatory backdrop. Goldman Sachs posted excellent first-quarter results, and the stock rose modestly after the earnings report. With that said, I think the investment bank stock could be a better buy than Wall Street thinks. Here's why. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Dealmaking activity continues to accelerate Goldman Sachs is one of the largest investment banks in the United States and leans heavily on capital markets for its business. The bank struggled a few years back, when capital markets activity slowed to a crawl while its consumer banking business struggled. The culprit was high interest rates and heavy regulatory scrutiny, which made companies more hesitant about pursuing major deals or IPOs. Over the past year, companies have found it easier to make deals thanks to faster regulatory approvals and strong equity markets. Streamlined regulatory processes have helped boost deals and enabled investment banks to get things done faster than expected, months ahead of schedule. In December, Goldman Sachs closed o...

日內瓦網球公開賽 錢亮拿贏得男單冠軍 【有線新聞】日內瓦網球公開賽，錢亮拿贏得男單冠軍。 藍衫錢亮拿決賽面對拿禾尼，先輸3比6。去年兩度在硬地交手各贏一次，首度在泥地碰頭，錢亮拿找到反勝方法，第二盤3次破發機會全數把握，以6比3扳平盤數。決勝盤領先3比0下被拿禾尼追平，4號種子的錢亮拿頂住壓力，尾段連贏兩局，贏7比5，盤數反勝2比1，出戰法網前打下強心針。錢亮拿贏得個人第二項巡迴賽錦標，世界排名新至個人新高的18。

AI-Fuelled AWS Growth, Alexa for Shopping and Legal Scrutiny Might Change The Case For Investing In Amazon.com (AMZN) simplywall.st

格隆汇5月24日｜美国总统特朗普：除了协议的许多其他要素外，霍尔木兹海峡将会开放。

格隆汇5月24日｜美国总统特朗普：伊朗协议的最终细节目前正在讨论中，预计将很快公布。

格隆汇5月24日｜美国总统特朗普：与以色列总理内塔尼亚胡的通话进展顺利。

德國盃決賽 拜仁慕尼黑挫史特加封王 哈利簡尼「帽子戲法」 【有線新聞】德國盃決賽，哈利簡尼大演「帽子戲法」，帶領拜仁慕尼黑以3比0大勝衛冕的史特加，2020年後再度封王。 奧利斯送入禁區，哈利簡尼被力逼下頂出底線。換邊後兩人再度連線，哈利簡尼這次就頂入了，紅衫拜仁55分鐘打破僵局。對上一次入德國盃決賽要數到2020年，當時贏利華古遜4比2捧盃，今季在甘賓尼帶領下已稱霸聯賽。 入球燃點球迷熱情，看台煙霧彌漫，濃煙導致比賽一度暫停。連續兩年殺入決賽，史特加無緣蟬聯錦標，基馬安達斯的頭槌不中目標。為英格蘭出戰世界盃前，哈利簡尼帶領拜仁第21次成為德國盃盟主，入到禁區轉身再射，80分鐘2比0。落後的史特加雪上加霜，史迪拿禁區犯手球，球證判罰12碼，哈利簡尼操刀，門將捉到路都入，補時2分鐘連中三元，亦是他今季各項賽事第61球。 拜仁贏3比0，重返德國國家隊的紐亞高舉獎盃，拜仁相隔6年再度封王。

格隆汇5月24日｜美国总统特朗普：伊朗协议已基本谈妥。

Viking Therapeutics (VKTX +0.68%) increasingly looks like an acquisition candidate in biotech. But why? It's because large pharmaceutical companies are desperate to secure obesity drug exposure, and Viking controls one of the more advanced independent GLP-1/GIP programs still available. Its lead obesity candidate, VK2735, is currently being developed in both injectable and oral formulations. The company's Phase 3 VANQUISH obesity studies are already fully enrolled, while management expects to initiate Phase 3 trials for the oral tablet later this year. The data for Viking's drug pipeline is strong In Viking's recent Phase 2 oral obesity study, patients achieved an average weight loss of up to 12.2% after 13 weeks, with no plateau observed during the trial. Earlier Phase 2 data involving the injectable version demonstrated up to 14.7% weight loss after 13 weeks. These results matter because the obesity market is becoming one of the largest pharmaceutical opportunities in decades. Analysts widely expect GLP-1 and dual agonist obesity therapies to eventually generate well over $100 billion annually. Eli Lilly and Novo Nordisk are already generating tens of billions in revenue from obesity and diabetes drugs like Zepbound and Wegovy. Here's the rub For large pharma companies, there aren't many late-stage obesity assets left to buy. That is where Viking becomes interesting. Unlike many smaller obesity drug developers, Viking still controls both injectable and oral versions of the same active molecule. Management also continues emphasizing potential maintenance dosing opportunities and additional metabolic indications beyond obesity itself. And financially, the company is relatively healthy for biotech stocks at this stage. Viking ended Q1 2026 with roughly $603 million in cash and investments, which management believes should fund operations into 2028. That reduces immediate financing pressure and gives the company flexibility during partnership or acquisition negotiatio...

What Happened? Shares of computer processor maker AMD (NASDAQ:AMD) jumped 4.7% in the afternoon session after the company confirmed it has started ramping up production of its next-generation 2-nanometer 'Venice' CPUs and announced plans to invest over $10 billion in Taiwan's AI supply chain, prompting bullish analyst upgrades. The new chips are being built using an advanced manufacturing process from partner TSMC. This development, along with CEO Lisa Su's comments on stronger-than-expected demand for AI infrastructure, fueled investor optimism. In response, several analysts raised their price targets, with Bank of America increasing its target to $500, citing a projected $1.7 trillion AI data-center market by 2030. The positive news adds to recent momentum, as reports showed AMD gained server CPU market share in the first quarter of 2026 while a key competitor's share decreased. After the initial pop the shares cooled down to $469.43, up 4.4% from previous close. Is now the time to buy AMD? Access our full analysis report here, it’s free. What Is The Market Telling Us AMD’s shares are extremely volatile and have had 38 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 2 days ago when the stock gained 8% on the news that traders positioned ahead of Nvidia's fiscal Q1 earnings. Nvidia accounted for a significant percentage of the S&P 500's gains heading into the announcement, making the print the binary catalyst for the entire AI-infrastructure complex — networking ASICs, connectivity silicon, memory, and packaging all move together on the read-through. Falling oil prices also supported the bullish sentiment. Semis carry arguably the longest-dated cash flows in the equity market because most of their value sits in 2027–2030 AI capex, not in the current quarter. When Brent ...

白宮附近傳槍響 槍手身份曝光 去年圖闖禁區、送往精神病院 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】美國一名男子靠近白宮向特勤人員開槍，他被擊斃，一名途人中彈受傷。總統特朗普事發時正在白宮官邸，沒有受影響，白宮一度封鎖。 「特朗普總統說即將達成協議，不過雙方仍有重大分歧。」美國廣播公司記者拍攝新聞報道時聽到多下槍聲，被要求由北草坪撤至新聞簡報室暫避的記者稱聽到十多至三十下槍聲。槍擊發生後警員封鎖現場，加緊巡邏。 傳媒報道，一名男子傍晚約6時在白宮附近的賓夕法尼亞大道及西北區17街交界，向檢查站的人員開了多槍，特勤人員還火。槍手中槍被制服，送院搶救不治。一名途人亦中槍，未清楚何人開槍打中他，沒有執法人員受傷。 調查消息指槍手是21歲的貝斯特，最近一年半居住華盛頓。上年7月已試過闖入白宮附近禁區，聲稱自己是耶穌，被捕後送往精神病院。事發時總統特朗普正在白宮官邸，沒有受影響，已聽取匯報，白宮一度封鎖40分鐘。 本月初白宮附近亦發生槍擊，一名男人在華盛頓紀念碑附近與特勤人員駁火，副總統萬斯的車隊事發前不久經過。特朗普上月出席白宮記者協會晚宴期間，槍手試圖突破安檢區域闖入宴會廳，槍手艾倫被控企圖暗殺總統等三項罪名。

Why AMD (AMD) Stock Is Up Today Yahoo Finance

長洲太平清醮｜飄色巡遊下午舉行 遊客：感覺人流不及往年 To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video 【有線新聞】長洲太平清醮飄色會景巡遊下午舉行，一早已有大批遊客到長洲。 長洲北帝廟外已搭好戲棚，不少善信前來上香，祈求保祐。重頭戲飄色巡遊下午舉行，大批遊客一早已到長洲。海傍越來越多人，消暑食物、紀念品店最有人氣。北社街這間老字號平安包店，門口已經排長龍等候買平安包，圖個好意頭，不少人一買便是一整盒。 負責人預計平安包銷量跟往年相若，有多年顧客指今年比去年少買兩盒，感覺今年人流不及往年。李先生：「送給朋友、自己又吃一些，每年如是。現在少了，以前買10盒的。（記者：覺得人多了嗎？）今年少了些，因為我年年都來，以前在這裡住的、在這裡長大。今年可能幾天假期，人們都北上了，我就很少回去的，多數都回來拜神。」 平安包店負責人郭先生：「如果只算平安包生意額是差不多，但我們有很多不同周邊，我們的平安包玩偶，甚至是外面的分銷點，那部分有升幅。近半年的人流是比去年同比較暢旺，我不知為何，可能因為『北上』去慣了，便去其他離島，返璞歸真。」

On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of Nektar Therapeutics (NASDAQ:NKTR) , an estimated $10.27 million trade based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Prosight Management increased its position in Nektar Therapeutics by 180,367 shares. The estimated value of the additional shares is $10.27 million, calculated using the average closing price for the quarter ending March 31, 2026. The quarter-end value of the firm’s Nektar Therapeutics stake rose by $29.43 million, a figure that includes both trading activity and share price appreciation. Nektar Therapeutics is a biotechnology company specializing in the development of novel therapeutics for oncology and immunology indications. The company leverages proprietary drug discovery platforms and strategic partnerships to advance a diverse clinical pipeline. Its focus on innovative biologics and collaborative R&D positions it to address significant unmet needs in the global healthcare market. Continue reading